# Imatinib in Dermatofibrosarcoma Protuberans (DFSP)

> **NCT00122473** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dermatologic Cooperative Oncology Group** · enrollment: 30 (—)

## Conditions studied

- Dermatofibrosarcoma

## Interventions

- **DRUG:** Imatinib (Glivec)

## Key facts

- **NCT ID:** NCT00122473
- **Lead sponsor:** Dermatologic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 30 (—)
- **Last updated:** 2011-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122473, "Imatinib in Dermatofibrosarcoma Protuberans (DFSP)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00122473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*